Seminar: Ran Jing
February 18, 2025
12:30 pm - 1:30 pm
LSC 3 (Life Sciences Institute - 2350 Health Sciences Mall)

Harnessing human pluripotent stem cells for T cell development and cancer immunotherapy
Dr. Jing's research leverages human pluripotent stem cells (iPSCs) to study lymphoid development and create stem cell-based immune cell therapies. His previous work demonstrated that EZH1 repression enhances lymphoid potential and generates developmentally mature T cells resembling peripheral blood αβ T cells (Cell Stem Cell, 2022). A small molecule screen further revealed that G9a/GLP inhibition promotes mature T cell generation, with epigenetically reprogrammed iPSC-CAR-T cells displaying enhanced antitumor activity and persistence (Cell Stem Cell, 2024). These findings uncover key regulators of T cell lineage choice and advance the development of iPSC-based adoptive T cell immunotherapies.
We honour xwməθkwəy̓ əm (Musqueam) on whose ancestral, unceded territory UBC Vancouver is situated. UBC Science is committed to building meaningful relationships with Indigenous peoples so we can advance Reconciliation and ensure traditional ways of knowing enrich our teaching and research.
Learn more: Musqueam First Nation